TMDX (TransMedics Group) LT-Debt-to-Total-Asset: 0.59 (As of Mar. 2026)

What is TransMedics Group LT-Debt-to-Total-Asset?

TransMedics Group TMDX +1.49% 69 LT-Debt-to-Total-Asset is 0.59 as of Mar. 2026. GuruFocus rates TMDX with a GF Score™ of 69/100 and a GF Value™ of $167.36 (Possible Value Trap). The stock has 9 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. TransMedics Group's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.59.

TransMedics Group's long-term debt to total assets ratio declined from Mar. 2025 (0.62) to Mar. 2026 (0.59). It may suggest that TransMedics Group is progressively becoming less dependent on debt to grow their business.

TransMedics Group (NAS:TMDX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

TransMedics Group LT-Debt-to-Total-Asset Related Terms

TransMedics Group LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for TransMedics Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransMedics Group LT-Debt-to-Total-Asset Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.33

0.24

0.73

0.64

0.47

TransMedics Group Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.62	0.58	0.54	0.47	0.59

69GF Score

TransMedics Group Inc TMDX

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

TransMedics Group LT-Debt-to-Total-Asset Calculation

TransMedics Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	505.968	/	1068.373
	=	0.47

TransMedics Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	844.907	/	1434.82
	=	0.59

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.59 mean?

TransMedics Group (TMDX) has a LT-Debt-to-Total-Asset of 0.59 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TransMedics Group and its competitors.

Is TransMedics Group's LT-Debt-to-Total-Asset too high?

TransMedics Group's current LT-Debt-to-Total-Asset is 0.59. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does TransMedics Group's LT-Debt-to-Total-Asset compare to AXGN and BFLY?

TransMedics Group's LT-Debt-to-Total-Asset of 0.59 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on TransMedics Group and its competitors. TransMedics Group's current LT-Debt-to-Total-Asset is 0.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is TransMedics Group stock overvalued right now?

Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $167.36, compared to a current price of $68.86 — trading 58.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.59. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For TransMedics Group (TMDX), the current LT-Debt-to-Total-Asset is 0.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TransMedics Group (TMDX) Overvalued in 2026?

Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued. The current stock price of $68.86 is trading 58.9% below its estimated GF Value™ of $167.36. GuruFocus considers TransMedics Group to be Possible Value Trap.

Key valuation signals for TMDX:

LT-Debt-to-Total-Asset: 0.59
GF Value™: $167.36 vs. price of $68.86 (58.9% below fair value)
GF Score™: 69/100 with 9 warning signs

No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TransMedics Group Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies AXGN BFLY ESTA NEOG UFPT ALMR NVCR ITGR IART ATEC ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges TMDX:Mexico 1TMDX:Italy TMDX:Germany

Address 200 Minuteman Road, Andover, MA, USA, 01810

Website https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

69GF Score

Get the complete analysis for TMDX

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$68.86

Price

$167.36

GF Value

View TMDX Analysis

See LT-Debt-to-Total-Asset data for all stocks →